Literature DB >> 16969149

Removal of methotrexate by peritoneal dialysis and hemodialysis in a single patient with end-stage renal disease.

Charles J Diskin1, Thomas J Stokes, Linda M Dansby, Lautrec Radcliff, Thomas B Carter.   

Abstract

BACKGROUND: Although methotrexate is highly bound to albumin, it is thought to be removed by hemodialysis and not by peritoneal dialysis. We are not aware of any direct comparison in the same patient. CASE REPORT/
METHODS: A 60-year-old patient on continuous ambulatory peritoneal dialysis was admitted to the East Alabama Medical Center for stomatitis and pancytopenia after being given 10 mg of methotrexate for his rheumatoid arthritis. Measurements of total methotrexate levels were made before, during, and after sequential peritoneal and hemodialysis treatments.
RESULTS: We found that the clearance of methotrexate measured in the dialysate was equal in the first hour of dialysis for both types of dialysis, although serum levels were markedly lower in hemodialysis compared to peritoneal dialysis.
CONCLUSION: Methotrexate was cleared by peritoneal dialysis in the first hour of an exchange and was not associated with a rebound in serum levels. Hemodialysis was associated with lower serum levels; however, there was also a significant rebound 2 hours after the procedure ended. Since neither procedure was able to preclude the death of the patient, other more effective means of methotrexate elimination should be employed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16969149     DOI: 10.1097/00000441-200609000-00013

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  8 in total

1.  High dose methotrexate and extended hours high-flux hemodialysis for the treatment of primary central nervous system lymphoma in a patient with end stage renal disease.

Authors:  Howard Mutsando; Magid Fahim; Devinder S Gill; Carmel M Hawley; David W Johnson; Maher K Gandhi; Paula V Marlton; Helen G Mar Fan; Peter N Mollee
Journal:  Am J Blood Res       Date:  2012-01-01

Review 2.  Methotrexate for rheumatoid arthritis patients who are on hemodialysis.

Authors:  Hasanein Al-Hasani; Euthalia Roussou
Journal:  Rheumatol Int       Date:  2011-07-22       Impact factor: 2.631

3.  Case files of the New York City Poison Control Center: antidotal strategies for the management of methotrexate toxicity.

Authors:  Silas W Smith; Lewis S Nelson
Journal:  J Med Toxicol       Date:  2008-06

4.  Extracorporeal Treatment for Methotrexate Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup.

Authors:  Marc Ghannoum; Darren M Roberts; David S Goldfarb; Jesper Heldrup; Kurt Anseeuw; Tais F Galvao; Thomas D Nolin; Robert S Hoffman; Valery Lavergne; Paul Meyers; Sophie Gosselin; Tudor Botnaru; Karine Mardini; David M Wood
Journal:  Clin J Am Soc Nephrol       Date:  2022-03-02       Impact factor: 10.614

5.  Cutaneous toxicity of oral low-dose methotrexate.

Authors:  Priyanka Jalandhara; Gurjit Kaeley
Journal:  Proc (Bayl Univ Med Cent)       Date:  2018-05-22

6.  Leflunomide in dialysis patients with rheumatoid arthritis--a pharmacokinetic study.

Authors:  Raoul Bergner; Lena Peters; Verena Schmitt; Christian Löffler
Journal:  Clin Rheumatol       Date:  2012-11-22       Impact factor: 2.980

7.  Combined acute interstitial pneumonitis and pancytopenia induced by low-dose methotrexate in a hemodialysis patient treated for bullous pemphigoid.

Authors:  Haibo Liu; Fang Liu; Min Zhang; Wenliang Yan; Hong Sang
Journal:  An Bras Dermatol       Date:  2015 May-Jun       Impact factor: 1.896

Review 8.  Successful multiple-exchange peritoneal dialysis in a patient with severe hematological toxicity by methotrexate: case report and literature review.

Authors:  Arbey Aristizabal-Alzate; John Fredy Nieto-Rios; Catalina Ocampo-Kohn; Lina Maria Serna-Higuita; Diana Carolina Bello-Marquez; Gustavo Adolfo Zuluaga-Valencia
Journal:  J Bras Nefrol       Date:  2018-09-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.